Amgen and Allergan Report Availability of Mvasi (biosimilar bevacizumab) and Kanjinti (biosimilar trastuzumab) in the US

Amgen and Allergan Report Availability of Mvasi (biosimilar bevacizumab) and Kanjinti (biosimilar trastuzumab) in the US

Shots:

  • The WAC cost of Mvasi and Kanjinti is 15% lower than their reference products i.e Avastin and Herceptin respectively. Mvasi is available at WAC of $677.40/100 mg and $2,709.60/400 mg single-dose vial and Kanjinti is being made available at a WAC of $3,697.26/420 mg multi-dose vial,
  • During launch Mvasi and Kanjinti will be 12% and 13% respectively lower to average selling price (ASP) of their reference products. The products were proved to be highly similar to, with no clinically meaningful differences in terms of safety and effectiveness from Avastin and Herceptin respectively based on analytical, clinical safety and efficacy data
  • Mvasi (bevacizumab-awwb) is an IgG1 mAb approved by the US FDA for 5 types of cancer, plus chemotherapy/interferon-alfa for mCRC, non-sq NSCLC, recurrent glioblastoma metastatic RCC and persistent, recurrent, or metastatic cervical cancer. Kanjinti (trastuzumab-anns) is a recombinant DNA-derived IgG1 kappa antibody all indications of reference product

Click here to read full press release/ article | Ref: Amgen | Image: Behance